1. In order to study the effects of chenodeoxy cholic acid on serum and biliary lipids in hyper lipoproteinaemia, chenodeoxycholic acid was ad ministered to seven type Ila, eight type lib and eight type IV patients in a daily dose of 750 mg (1 -9 mmol) for 3 months.
Introduction
Oral chenodeoxycholic acid may lower cholesterol saturation of bile and induce gallstone dissolution (Bell, Whitney & Dowling, 1972; Correspondence: Dr Kurt Einarsson, Department Medicine, Serafimerlasarettet, S-l 12 83 Stockholm, Sweden.
of Hofmann, Schoenfield & Thistle, 1972; Hofmann & Paumgartner, 1975) . During such therapy, a fall in serum triglycerides has been observed whereas serum cholesterol is unaffected (Bell, Lewis, Petrie & Dowling, 1973; Hoffman, Hofmann & Thistle, 1974; Iser, Dowling, Mok & Bell, 1975) . As hypertriglyceridaemia per se appears to be linked to an increased risk of gallstone development (Einarsson, Hellström & Kallner, 1975) and as triglyceride-lowering agents such as clofibrate increase biliary cholesterol saturation (Pertsemlides, Panveliwalla & Ahrens, 1974) and gallstone incidence (Coronary Drug Project, 1975; Cooper, Geizerova & Oliver, 1975) , chenodeoxycholic acid may be useful in treatment of hypertri glyceridaemia. Previous studies have reported a significant reduction (Miller & Nestel, 1974) as well as no changes (Schlierf, Stiehl, Heuch, Lang, Oster & Schellenberg, 1976) in serum triglycerides in hypertriglyceridaemic patients treated with chenodeoxycholic acid, whereas no information on changes in biliary lipids in these patients is presently available. We thus decided to study the effect of chenodeoxycholic acid on serum and biliary lipids in patients with hyper lipoproteinaemia.
Material and methods
We studied 23 outpatients with hyper lipoproteinaemia, all of whom gave their informed consent to participate. (The investigation was approved by the Ethical Committee of the Karolinska Institutet.) Diagnostic criteria for lipoprotein patterning (Beaumont, Carlson, Cooper, Fejfar, Fredrickson & Strasser, 1970) are given elsewhere (Einarsson, Hellström & Kallner, 1974) . 451
Seven patients (four males and three females) had type Ila, eight (two males and six females) type lib, and eight (six males and two females) type IV hyperlipoproteinaemia. An oral cholecystogram was performed in all non-cholecystectomized sub jects. Gall-bladder disease was found in one type Ila, five type lib and four type IV patients. Some of the patients were continuously treated with digitalis, diuretics and/or /?-adrenoreceptorblocking agents; all medication was unchanged before and during the studies. One type IV patient had a mild diabetes, controlled by sulphonylurea.
After a control period of 3-4 weeks, the patients were given 750 mg (1-9 mmol) of chenodeoxycholic acid (Chendol, AB Draco, Lund, Sweden) daily in two divided doses (the approved ex perimental dose at the time) for 3 months. Body weight, serum lipids and liver function tests were determined before and at 4-week intervals during treatment.
Seventeen of the patients were examined with regard to biliary lipids under metabolic ward conditions before and at the end of the treatment period. After 4-7 days on a standardized diet of natural type (see Einarsson et al., 1974) , fasting duodenal bile was obtained on 2 consecutive days as described previously (Ahlberg, Angelin, Einarsson, Hellström & Leijd, 1977) .
Total bile acids (Fausa & Skälhegg, 1974) , cholesterol (Hanel & Dam, 1955) and phospholipids (Bartlett, 1959) were determined as described (Ahlberg et al., 1977) . The cholesterol content was expressed as a molar percentage of total biliary lipids: 100 x cholesterol (mol)/[cholesterol + bile acids + phospholipids (mol)]. Saturation of bile with cholesterol was calculated in terms of lithogenic indices (Thomas & Hofmann, 1973) , by using both the solubility limits of Admirand & Small (1968) and of Hegardt & Dam (1971) , and Holzbach, March, Olszewski & Holan (1973) .
Bile acid composition was determined as described previously (Ahlberg et al., 1977) with the exception that the methyl trimethylsilyl ethers were analysed by gas-liquid chromatography on a 1% Hi-Eff 8BP column.
Significance of differences were evaluated with the paired /-tests and of linear regressions by estimating the correlation coefficient, r (Snedecor & Cochran, 1974) . Mean values are given ±SEM.
Results
Body weights remained constant in all cases during treatment with chenodeoxycholic acid. Seven patients developed mild transient diarrhoea and for four of them the dose had to be reduced for some days. Serum aspartate aminotransferase (EC 2.6.1.1) and alanine aminotransferase (EC 2.6.1.2) rose significantly after 4 weeks of therapy but in all cases returned to normal after treatment ended.
Serum cholesterol concentrations remained un changed in all types of hyperlipoproteinaemia during treatment with chenodeoxycholic acid (Table 1) . Serum triglycerides fell in type lib and in type IV hyperlipoproteinaemia. In all patients taken together, the triglycerides were reduced 15-20% during the treatment period.
The proportion of chenodeoxycholic acid in bile increased in all subjects, from 28-8 ± 1-5 to 72.4 + 3-6% (P < 0-001), and the proportions of cholic acid and deoxycholic acid decreased reciprocally, from 41-2 ± 2-6 to 11-5 ± 1-6% (P < 0-001) and from 29-6 ± 3-6 to 11-2 ± 2-5% (J> < 0-001) respectively. Ursodeoxycholic acid was present in trace or small amounts in only three patients before treatment, and was increased by treatment with chenodeoxycholic acid, from 0-2 + 0-2 to 3-2 + 0-7% {P < 0-001). Similarly, lithocholic acid was present in small amounts in four patients before treatment and also showed a rise during medication, from 0-2 ± 0-2 to 1-7 ± 0-4% (P < 0-005). No patients with type Ila hyper lipoproteinaemia displayed an increase in litho cholic acid.
The mean biliary cholesterol saturation and the lithogenic indices decreased in all patients but one type lib (Table 1) . A lithogenic index (Hegardt & Dam, 1971; Holzbach et al., 1973) of >1·0 indicates supersaturated bile. Before treatment, all patients except one type Ila and one type lib had an index >l-0. During treatment, three type lib and five type IV patients still had an index > 1 -0.
The cholesterol concentration (% of total biliary lipids) and cholesterol saturation correlated negatively with the proportion of chenodeoxycholic acid in biliary bile acids (r = -0-65, P < 0-001, and r = -0-67, P < 0-001 respectively; n = 34) but positively with serum triglycerides (r = +0-47, P < 0-01, and r = +0-48, P < 0-01 respectively; n = 34). The change in lithogenic index correlated weakly but significantly with the change in serum triglycerides (r = +0-51, P < 0-05; n = 17). (7) 9-4 + 0-2 9-6 + 0-4 Type lib (8) 9-3 + 0-7 9-1 +0-8 Type IV (8) 7-1 ±0-3 7-6 + 0-4 Total (23) 8-6 + 0-3 8-8 ±0-4
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Serum triglycerides (mmol/1) Type Ha (7) 1-7 + 0-1 1-4 ±0-2 Type lib (8) 3-6 + 0-4 2-4 + 0-2** Type IV (8) 4-7+0-5 3-9 + 0-5 Total (23) 3-3 + 0-3 2-6 ± 0-3**** Biliary cholesterol (% of total biliary lipids) Type Ha (4) 9-1 ± 1-3 Type lib (5) 9-0+1-0 Type IV (8) 
Discussion
Bile acid formation in man is regulated by a negative feedback control triggered by the amount of bile acids reaching the liver via the portal vein (Hofmann, 1976) . Expansion of the chenodeoxy cholic acid pool is associated with a reduced pool size and formation of both cholic acid and deoxycholic acid (Danzinger, Hofmann, Thistle & Schoenfield, 1973; Kallner, 1975) . In the present study, after 3 months of treatment chenodeoxy cholic acid constituted about 70% of the biliary bile acids. The small increases of ursodeoxycholic acid and lithocholic acid are well known from studies in normolipidaemic patients (e.g. Bremmelgaard & Pedersen, 1976; Thistle, Hofmann, Yu & Ott, 1977; Danzinger et al, 1973; Coyne, Bonorris, Chung, Goldstein, Lahana & Schoenfield, 1975; Stiehl, Raedsch & Kommerell, 1975) .
At the dose administered, chenodeoxycholic acid reduced bile cholesterol saturation in all patients except one. However, half of the patients still had an oversaturated bile. The saturation index correlated with the percentage of chenodeoxycholic acid in duodenal bile, and above 80% chenodeoxy cholic acid only one patient had saturated bile. The dose of chenodeoxycholic acid, about 10 mg/kg, may have been too low, as Iser et al. (1975) now recommend 14-15 mg/kg for non-obese subjects.
Administration of chenodeoxycholic acid was followed by a 15-20% decrease in serum triglycerides. Miller & Nestel (1974) have shown decreases of triglyceride concentration to parallel reduction of the very-low-density lipoprotein frac tion. They suggested that chenodeoxycholic acid inhibits triglyceride production. We have found (B. Angelin, K. Einarsson, K. Hellström & B. Leijd, unpublished work) that chenodeoxycholic acid decreases triglyceride synthesis by 20-30% in hyperlipidaemia.
The parallel decrease in serum triglyceride concentrations and bile cholesterol and the inhibition of bile acid synthesis by chenodeoxy cholic acid (Kallner, 1975) suggests an integrated regulation of these variables (cf. Hellström, Angelin, Einarsson, Kallner & Leijd, 1977) . We have shown that type IV hyperlipoproteinaemia is associated with an increased occurrence of gall bladder disease (Einarsson et al., 1975) and an elevated biliary cholesterol saturation (J. Ahlberg, B. Angelin, K. Einarsson, K. Hellström & B. Leijd, unpublished work) . The lowering of biliary cholesterol that accompanies the decrease of triglyceride during treatment with chenodeoxy cholic acid may thus make this compound a useful adjunct in hypolipidaemic therapy.
